Detection of Melanoma Nodal Metastases; Differences in Detection Between Elderly and Younger Patients Do Not Affect Survival by Kruijff, S. et al.
ORIGINAL ARTICLE – MELANOMAS
Detection of Melanoma Nodal Metastases; Differences
in Detection Between Elderly and Younger Patients
Do Not Affect Survival
S. Kruijff, MD
1, E. Bastiaannet, MSc
1, A. J. H. Suurmeijer, MD, PhD
2, and H. J. Hoekstra, MD, PhD
1
1Surgical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands;
2Pathology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
ABSTRACT
Background. Melanoma lymph nodes metastases may be
detected by patients or by physicians. Understanding the
outcomes of self-detection or physician detection is
essential for the design of follow-up studies. We evaluated
the role of the method of detection in nodal disease in the
prognosis of melanoma patients who underwent therapeutic
lymph node dissection (TLND).
Materials and Methods. All melanoma patients with
palpable lymph nodes were included in a prospective
database (n = 98), and the method of detection was
recorded. Detection of lymph node metastases compared
with pathological ﬁndings in the TLND was assessed by
multivariate logistic regression. Disease-free survival
(DFS) and disease-speciﬁc survival (DSS) were assessed
by univariate and multivariate Cox proportional hazard
analysis.
Results. Nodal metastases were detected by physicians in
45% and by patients in 55% (P\0.001). Age was sig-
niﬁcantly associated with method of detection. Patients
B60 years detected 69% their lymph node metastases as
opposed to 32% of patients[60 years (odds ratio [OR] 0.3;
P = 0.007). However, this was not associated with prog-
nostic ﬁndings in TLND, number of positive nodes, tumor
size, or extranodal spread. Method of detection or age at
the time of nodal metastases was not signiﬁcantly associ-
ated with 2-year DFS or DSS.
Conclusions. 45% of all lymph node metastases in stage
I–II melanoma patients are physician detected. Younger
patients detect their own lymph node metastases signiﬁ-
cantly more often than elderly patients. However, neither
the method of detection nor age correlates with DSS. More
frequent follow-up would not alter DFS and DSS
signiﬁcantly.
The incidence of melanoma is increasing worldwide. In
the Netherlands, the incidence increased from 9.5 to 13.7
per 100,000 in men and from 13.4 to 18.5 per 100,000 in
women between 1989 and 2003. Approximately 90% of
patients have stage I or II melanoma at diagnosis, and the
incidence of patients with a thin melanoma has
increased.
1–5 Although the early diagnosis of cutaneous
melanoma with small Breslow’s tumor thickness has been
responsible for the leveling off of overall melanoma mor-
tality, the incidence at the same time has continued to rise.
6
The number of melanoma patients requiring follow-up
surveillance has doubled in the Netherlands.
1 Despite
improved public awareness and earlier diagnosis and
treatment, mortality from melanoma increased from 2.5 to
3.6/100,000 in men and from 2.0 to 2.4/100,000 in women
in the Netherlands between 1989 and 2003.
1
Several studies have been performed concerning survival
in patient-detected versus physician-detected recurrences.
Because most of ﬁrst melanoma recurrences are detected
by patients or their partners, the value of high-frequency
follow-uphasoftenbeen questioned.
7,8Overhalf ofpatients
(55%) with early-stage melanoma detect their own recur-
rence(s).
9–20 In recent decades, several follow-up schedules
have been suggested with large variations and without
international consensus.
3 Proposals for these schedules are
based on risk calculations concerning melanoma recurrence
andcosteffectiveness.Severalauthorshaverecommendeda
reduction in the intensity of follow-up regimens based on
these factors.
9–11,21 Others claim that a more intensive
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12,22,23
Of the various follow-up methods performed by physi-
cians, only medical history and physical examination seem
tobecosteffective.
20Despitetheseﬁndings,mostmelanoma
patients are still followed up on a frequent basis, mostly for
education, reassurance, or inclusion in clinical trials.
Studies concerning the method of nodal metastasis
detection have not shown a difference in survival com-
paring physician-detected versus patient-detected
recurrences. Intense follow-up does not seem to contribute
to disease-free interval or overall survival, as physician-
detected lesions do not have a better prognosis than those
detected by patients themselves.
3,16
Patients with clinical stage IIIb melanoma (palpable
lymph node metastases) have a 5-year survival of 59%.
24 A
better understanding of the method of detection of palpable
melanoma metastases (i.e., by patient or physician) and its
inﬂuence on survival is essential to resolve the aforemen-
tioned follow-up controversy.
The aim of this study was to evaluate the role of the
method of detection, by patient or physician, in melanoma
patients with palpable lymph nodes and to analyze the
association with pathological ﬁndings in therapeutic lymph
node dissection (TLND) and the impact of the detection
method on disease-free and disease-speciﬁc survival. The
method of detection of positive nodes (patient versus phy-
sician)mightnotonlyhaveimpactonsurvivalbutmightalso
inﬂuencethenumberofpositivenodes,thetumorsize,orthe
presence of extranodal growth in the TLND.
MATERIALS AND METHODS
Patients with primary melanoma were treated with wide
local resection (1 or 2 cm) with or without sentinel lymph
node biopsy and, if indicated, therapeutic lymph node
dissection. Stage I and II melanoma patients were followed
after treatment in accordance with the Dutch National
Guideline Treatment of Melanoma (www.oncoline.nl).
Postoperative follow-up included physical examination
every 3 months for the ﬁrst year, every 4 months for the
second year, and every 6 months thereafter. Standard
radiographic or serum investigations were not performed.
All patients with clinically and cytologically proven
lymphnodemetastasesofmelanoma(AJCCstageIIIb)were
included in this study. If palpable positive nodes were found
during regular follow-up, this was recorded as ‘‘physician-
detected nodal metastases.’’ When positive palpable nodes
wererecordedafterapatient-initiatedvisit,thiswasrecorded
as ‘‘patient-detected nodal metastases.’’ Patients without
distant metastases on ﬂuorodeoxyglucose-positron emission
tomography (FDG-PET) and computed tomography (CT)
receivedaTLNDwithcurativeintentandwereenteredintoa
single prospective institutional database. The stage IV
upstaged patients were referred for further palliative treat-
ment to their primary physician, medical oncologist, or
radiation oncologist and excluded for further follow-up.
Patients who presented with local recurrence or in-transit
disease were not included.
Patients with nodal metastases of C3 cm and/or
C3 positive lymph nodes and/or extranodal (EN) dis-
ease received adjuvant radiotherapy (20 9 2.4 Gy). Data
examined include patient demographics, clinical and his-
topathologic characteristics of the tumor, date and type of
operation, site and date of ﬁrst (nodal) and second recur-
rence, method of detection of recurrence (i.e., patient or
physician during standard follow-up), and status at last
follow-up.
The study was approved by the Medical Ethical Com-
mittee of the University Medical Centre Groningen
(UMCG).
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FIG. 1 Kaplan–Meier curve DSS melanoma patients with positive
lymph nodes detected by physician versus detected by patient
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FIG. 2 Kaplan–Meier curve DFS melanoma patients with positive
lymph nodes detected by physician versus detected by patient
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For retrospective analysis, patients were divided by age
(B60 versus [60 years of age). Factors associated with
method of detection were analyzed by univariate and
multivariate logistic regression analysis. Four subgroups
were generated based on the combinations of young versus
elderly and physician versus patient detection to assess for
associations with pathological variables. Factors associated
with disease-free survival (DFS) and disease-speciﬁc sur-
vival (DSS) were assessed by univariate and multivariate
Cox proportional hazard analysis. For DFS, any recurrence
was recorded as an event; for DSS, death resulting from
melanoma was considered an event. Follow-up was trun-
cated at 4 years.
RESULTS
Patients
In the period 2003–2008, 98 patients [54 males (55.1%)
and 44 females (44.9%), median age 57.7 years (range
28.5–86.7)] with stage IIIb melanoma, based on PET and
spiral CT, underwent a TLND (Table 1). Median time from
primary melanoma treatment to nodal recurrence or nodal
recurrence of an unknown primary melanoma was 22.0 (0–
315.3) months.
Detection
Physicians detected 45% of the nodal metastases and
patients detected 55% (P = 0.001; Table 2). Of the 61
patients in the younger age group (B60 years), 19 nodal
metastases were physician detected (31%) whereas 42
nodal metastases were patient detected (69%). Of the 37
elderly patients ([60 years), 12 nodal metastases were
patient detected (32%) and 25 nodal metastases physician
detected (68%; P = 0.001).
Table 2 also shows the results of univariate and multi-
variate logistic regression analysis of the association
between method of detection and pathological information
from the lymph node dissection, sex, age, and nodal-
bearing area (axilla, groin, neck). Age was signiﬁcantly
associated with method of detection: 69% of patients
B60 years detected their nodal metastases versus 32% of
the patients[60 years (odds ratio [OR] 0.3; P = 0.007 in
multivariate analysis).
Patients with a thin primary melanoma had a higher
ratio of patient-detected positive lymph nodes (P = 0.05).
This was, however, not statistically signiﬁcant in multi-
variate analysis.
Sex, regional nodal basin site, number of nodes
removed, number of positive nodes, tumor size, and
extranodal growth were not associated with method of
detection in multivariate analysis.
There were no signiﬁcant differences in pathologi-
cal ﬁndings when the groups were divided in 4 groups:
patient-detected younger age (B60 years), patient-detected
TABLE 1 Patient and tumor characteristics of 98 patients with
clinically and cytological proven lymph node metastases of mela-
noma (AJCC stage IIIb)
Number Percentage
Sex
Male 54 55.1
Female 44 44.9
Age (years)
B60 61 62.2
[60 37 37.8
Primary melanoma
Localization
Upper extremities 11 11.2
Head and neck 8 8.2
Lower extremities 39 39.8
Trunk 34 34.7
Unknown primary 6 6.1
Breslow thickness
B2.0 43 43.9
[2.0 49 50.0
Unknown 6 6.1
Clark level
I–III 33 33.7
IV–VI 59 60.2
Unknown 6 6.1
Ulceration
Yes 22 22.5
No 76 77.5
Lymph node metastases
Lymph node dissection
Axilla 34 34.7
Groin 50 51.0
Neck 14 14.3
Number of nodes removed
\15 48 49.0
15 or more 50 51.0
No. of positive nodes
2 or less 53 54.1
[2 45 45.9
Tumor size (cm)
B3.0 62 63.3
[3.0 36 36.7
Extranodal growth
Yes 27 27.5
No 71 72.5
3010 S. Kruijff et al.elderly age ([60 years), physician-detected younger
age (B60 years), and physician-detected elderly age
([60 years).
Survival
Multivariate analysis showed no signiﬁcant difference in
2-year DFS for physician-detected versus patient-detected
nodal recurrences (Table 3). Univariate analyses showed
that DFS was associated with the lymph node bearing area,
the number of positive nodes, node size, and extranodal
growth pattern.
The 2-year DSS in males (53%) was signiﬁcantly
shorter than that in females (75%; HR 0.3; P = 0.004).
DSS was signiﬁcantly reduced in patients with C2 positive
nodes (51%) compared with patients with \2 positive
nodes (72%; hazard ratio [HR] 2.2; P = 0.03). Multivari-
ate analysis showed no signiﬁcant differences for DSS
related to age, Breslow thickness, ulceration, lymph node
bearing area (axilla, groin, neck), number of removed
nodes (B15 or[15 nodes), tumor size (B 3o r[3 cm), or
extranodal growth (Table 3). Although in univariate
analysis a trend in DSS was noted (P = 0.08) in favor of
the physician-detected group, in multivariate analysis,
when compared with detection by patients, no signiﬁcant
difference could be found (Figs. 1, 2).
DISCUSSION
The most efﬁcacious follow-up scheme for melanoma
patients is uncertain. Understanding the impact of the
method of detection of nodal recurrence on prognosis is
important in determining the most appropriate follow-up.
Despite controversy about follow-up in melanoma, our
results show that nodal metastases are still detected by
physicians in almost 45% of the patients. Young patients
detect their own lymph node metastases signiﬁcantly more
often than older patients (68% vs. 32%) (P = 0.007).
However, in patients undergoing close clinical surveillance
neither the method of detection (patient versus physician)
nor age seems to have a signiﬁcant inﬂuence on 2-year
DSS or DFS. Furthermore, no correlation could be found
between the methods of detection and the number of
positive nodes, lymph node size, or extranodal growth.
Despite this encouraging percentage of almost 45%
detected nodes by physicians, this rate does not seem to
result in any survival advantage. Earlier follow-up studies
describe an increasing controversy about the efﬁcacy of an
TABLE 2 Detection of lymph
node metastases in association
with pathological results of
lymph node dissection
Overall: 44.9% detected by
physician and 55.1% by patients
(P\0.001)
Patient-detected (%) Univariate analysis Multivariate analysis
OR (95% CI) P value OR (95% CI) P value
Sex 0.13 0.20
Male 48.2 1.0 1.0
Female 63.6 1.9 (0.8–4.3) 1.8 (0.7–4.6)
Age 0.001 0.007
B60 68.9 1.0 1.0
[60 32.4 0.2 0.3 (0.1–0.7)
Breslow thickness 0.05 0.22
B2.0 67.4 1.0 1.0
[2.0 42.9 0.4 (0.2–0.8) 0.5 (0.2–1.3)
Unknown primary 66.7 0.9 (0.2–5.9) 2.1 (0.3–15)
Lymph node region 0.56
Axilla 61.8 1.0
Groin 50.0 0.6 (0.3–1.5)
Neck 57.1 0.8 (0.2–2.9)
Nodes removed 0.53
\15 58.3 1.0
C15 52.0 0.7 (0.3–1.7)
Positive nodes
B2 47.2 1.0 0.09 1.0 0.17
[2 64.4 2.0 (0.9–4.6) 1.9 (0.7–4.9)
Tumor size (cm) 1.2 (0.9–1.6) 0.09 1.2 (0.9–1.6) 0.17
Extranodal growth
Yes 66.7 1.0 0.16 1.0 0.48
No 50.7 0.5 (0.2–1.3) 0.7 (0.2–2.0)
Detection Nodal Melanoma Recurrences 3011intensive follow-up scheme for melanoma patients as is
still organized in a lot of hospitals today.
This is the ﬁrst study evaluating the method of detection
of nodal recurrence in stage IIIb melanoma and the impact
of patient- or physician-detected nodal metastases on
survival.
Patients with clinical stage IIIb melanoma (palpable
lymph node metastases) have a 5-year survival of 59%.
24
The most well-recognized causes for this low survival rate
is the variation in the number of positive nodes, tumor size,
and presence of extranodal growth.
Another cause for low survival rates in this patient
category might be understaging. Bastiaannet et al. revealed
that staging with FDG-PET of clinically stage IIIb patients
resulted in upstaging of 22% to stage IV. In 19% treatment
was changed, usually from surgery to systemic treatment.
25
Patients in our current study were all staged with FDG-PET
and CT and therefore can be considered as ‘‘true’’ AJCC
stage IIIb patients.
Survival might also be inﬂuenced by follow-up and
method of detection. We expected physician-detected
positive lymph node status to correlate with a lower
number of positive nodes, smaller tumor size, and absence
of extranodal growth in the TLND. This association was
not found despite a positive trend in DSS (P = 0.08) in the
advantage of physician-detected nodes (Table 3).
Follow-up of melanoma has different purposes: to detect
ﬁrst melanoma recurrence, to assess treatment efﬁcacy,
and to detect a second primary melanoma (2–6%).
26–28
Also of great importance are patient reassurance and
TABLE 3 Disease-speciﬁc survival (DSS) and disease-free survival (DFS) in melanoma patients AJCC stage IIIb in correlation to detection by
physician versus detection by patient
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
DSS HR P value HR P value DFS HR P value HR P value
Sex 0.02 0.004 0.62
Male 53.2 1.0 1.0 35.2 1.0
Female 75.4 0.4 0.3 36.8 0.9
Age 0.28 0.17
B60 59.7 1.0 29.7 1.0
[60 66.6 0.7 45.2 0.7
Breslow thickness 0.81 0.83
B2.0 65.8 1.0 45.4 1.0
[2.0 64.5 0.9 30.4 1.06
Ulceration 0.61 0.21
Yes 61.5 1.0 22.6 1.0
No 62.8 0.8 40.5
Lymph location 0.37 0.07 0.2
Axilla 57.2 1.0 38.8 1.0 1.0
Groin 60.5 0.8 26.0 1.3 1.2
Neck 78.6 0.5 66.7 0.4 0.4
Nodes removed 0.9 0.78
\15 63.2 1.0 39.2 1.0
C15 61.8 1.1 32.9 1.1
Positive nodes 0.02 0.03 0.009 0.1
B2 72.5 1.0 1.0 46.7 1.0 1.0
[2 51.4 2.2 2.2 23.8 2.0 1.6
Tumor size 0.06 0.39 0.01 0.2
B3.0 69.6 1.0 1.0 45.3 1.0 1.0
[3.0 47.9 1.9 1.4 17.3 2.0 1.5
Extranodal growth 0.52 0.03 0.2
Yes 56.8 1.0 27.6 1.0 1.0
No 64.8 0.8 39.4 0.6 0.7
Detected by 0.08 0.14 0.2 0.5
Physician 67.6 1.0 1.0 36.2 1.0 1.0
Patient 58.4 1.8 1.7 36.6 1.4 1.2
3012 S. Kruijff et al.documentation or inclusion for clinical trials. Follow-up
schemes are often of high intensity; however, resources in
many centers are insufﬁcient to deal with the increasing
patient load. Therefore, identifying and integrating evi-
dence concerning the efﬁcacy of follow-up strategies is
important.
In 2003 Garbe et al. performed a prospective follow-up
study in melanoma patients following an intensive follow-
up scheme (every 3 months for the ﬁrst 5 years and every
6 months during the 6th to 10th years).
12 The authors
claimed that 83% of all recurrences were detected by a
physical examination during regular follow-up, and only
17% were detected by patients themselves. However, var-
ious AJCC melanoma stages were included in this study.
Francken et al. performed a large retrospective study and
found that only 62% of all types of recurrences were
identiﬁed by patients themselves; however, three-quarters
of ﬁrst melanoma recurrences (FMR) were detected by
patients or their partners, of which 11% were found by self-
examination.
3 In the present study, no signiﬁcant survival
difference was found comparing patient-detected versus
physician-detected nodal metastasis.
Additionally, patient age did not seem to have a sig-
niﬁcant inﬂuence on 2-year DSS or DFS. In patients older
than 60 years, almost 70% of the detected nodes were
found by a physician; in contrast, patients at or below
60 years of age detected their own nodes 70% of the time.
Earlier literature reports age as an independent prognostic
factor, perhaps presenting a surrogate for declining host
defense mechanism associated with advancing age.
2
Numerous studies have demonstrated that older patients
have a lower survival rate, especially those over 60 years
of age.
29–34 The older patient might not detect positive
lymph nodes because of a certain physical negligence that
occurs with aging. However, our results surprisingly did
not identify any survival disadvantage associated with
delayed detection of nodal metastases. This might be
explained by a small patient population or a follow-up
period that is too short. Another explanation could be
related to the recent report by Conway et al., who found
that lymphatic function declines with age.
35 Hypotheti-
cally, in older patients, declining lymphatic function might
modify metastatic patterns and slow the process of
dissemination.
Overall, it can be concluded that no study to date has
proven any disease-free survival or overall survival beneﬁt
related to intense follow-up surveillance as there are no
prospective studies that compare high-frequency to no or
low-frequency follow up.
With the frequency of follow-up that was used in this
study, the DFS and DSS for patients capable themselves of
detecting a palpable node in the regional nodal basin and
those unable to do so, were not signiﬁcantly different.
Otherwise stated, it could be concluded that the above
frequency of follow-up is sufﬁciently close for the detec-
tion and treatment of nodal disease. More frequent follow-
up probably would not alter the DFS and DSS signiﬁcantly.
Therefore, arguments for more frequent follow-up than the
aforementioned scheme are hard to justify as physician-
detected lesions do not have a better prognosis than those
detected by patients.
3,7,8 Whether follow-up with sparser
intervals could be designed in a responsible way cannot be
answered by this study.
Prospective, randomized, high-quality methodological
research is required in order to develop meaningful appli-
cable guidelines. Currently, no international consensus has
been reached concerning the optimal frequency of follow-
up visits for melanoma patients. Follow-up should be based
on individual patient characteristics; multiple patient fac-
tors should be used to design the most appropriate follow-
up.
36 A clinical randomized trial (MELFO) is currently
underway at the University Medical Centre Groningen to
evaluate the safety and cost effectiveness of reduced fol-
low-up surveillance.
37 In this RCT a high-frequency
follow-up scheme will be compared with a less-frequent
and better differentiated follow-up scheme adjusted to
melanoma AJCC stage.
In conclusion, more than 55% of lymph node metastases
in melanoma are detected by the patient. Younger patients
detect their own lymph node metastases signiﬁcantly more
often than elderly patients without any impact on DSS and
DFS. The data of our study will add to the controversy
about the value of high-frequency follow-up regimens in
melanoma. Prospective, randomized, high-quality meth-
odological research has been started to develop meaningful
applicable guidelines (MELFO).
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